PRME at a glance
Prime Medicine, Inc. (PRME, SEC CIK 1894562) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as June 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Prime Medicine, Inc. (PRME) reported revenue of $4.6 million (up 55.3% from FY2024) and a net loss of $201.1 million. Diluted EPS was -$1.35.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Prime Medicine, Inc. (PRME) shares worth $230.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.6M
- +55.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $230.5M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New collaborator risk triggered by Beam arbitration over PM647 and AATD program scope
- Beam arbitration resolved July 6, 2026, declaring PM647 within Prime’s Field and denying Beam damages and injunctive relief
- Regulatory and compliance exposure from Broad Institute march-in rights covering all gene targets
- Operational dependence on third-party licensors controlling prosecution and maintenance of Prime’s key patents
- Competitive risk from nonexclusive licenses allowing third parties access to Prime Editing technology
AI summary of the PRME 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Business highlights included alongside financial results
Item EX-99.1: Item EX-99.1
- Q2 net loss narrowed to $42.1M from $52.6M, while R&D fell to $33.4M from $41.4M
- Cash, investments, and restricted cash totaled $108.8M at June 30, 2026, with funding expected into 2027
Item 8.01: Other Events
- Arbitration victory confirms PM647 falls within Prime’s contractual “Field” for AATD treatment
- Tribunal found no breach of the 2019 Beam collaboration and license agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
- 140,384,724 shares represented, establishing quorum from 180,615,889 shares outstanding
- Michael Kelly and David Schenkein elected Class I directors through 2029
AI summaries of PRME 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PRME
Don't miss the next PRME filing
- Alerts as it files. A push when PRME files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PRME, by share count.
- Ask anything. An AI agent that reads every PRME filing and answers with sources.
PRME alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schenkein David P | A | Jun 5, 2026 | 75,000 | - |
| Chung Wendy | A | Jun 5, 2026 | 75,000 | - |
| Cahill Thomas | A | Jun 5, 2026 | 75,000 | - |
| NELSEN ROBERT | A | Jun 5, 2026 | 75,000 | - |
| Foster-Cheek Kaye I | A | Jun 5, 2026 | 75,000 | - |
| Kelly Michael Aaron | A | Jun 5, 2026 | 75,000 | - |
| Marrazzo Jeffrey D | A | Jun 5, 2026 | 75,000 | - |
| Makhni Svetlana Ni | A | Apr 16, 2026 | 800,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.0M | $4.6M |
| Operating Income | - | -$202.5M | -$208.3M |
| Net Income | -$198.1M | -$195.9M | -$201.1M |
| Op. Margin | - | -6787.4% | -4498.1% |
| Net Margin | - | -6566.6% | -4342.4% |
| Balance Sheet | |||
| Total Assets | $193.9M | $297.5M | $342.7M |
| Equity | - | $153.1M | $120.9M |
| ROE | - | -127.9% | -166.4% |
| Per Share | |||
| EPS | $-2.18 | $-1.65 | $-1.35 |
| Cash Flow | |||
| Operating CF | - | -$122.9M | -$162.6M |
| CapEx | $8.7M | $7.3M | $4.5M |
Source: XBRL data in Prime Medicine, Inc. (PRME)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PRME share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $230.5M |
| Q1 2026 | 28 | $189.5M |
| Q4 2025 | 26 | $190.9M |
| Q3 2025 | 25 | $259.6M |
| Q2 2025 | 23 | $84.4M |
| Q1 2025 | 19 | $61.8M |
| Q4 2024 | 16 | $95.5M |
| Q3 2024 | 15 | $100.5M |
- Goldman Sachs Group+2.46M (+254%)
- ARK Investment Management+2.10M (+34%)
- Citadel Advisors LLC+1.72M (+511%)
- State Street Corp+1.23M (+19%)
- BlackRock+1.10M (+13%)
- D.E. Shaw & Co−744.7K (-53%)
- Renaissance Technologies LLC−623.6K (-84%)
- AQR Capital Management−436.9K (-79%)
- Wells Fargo & Co−67.8K (-21%)
- Two Sigma Investments−48.3K (-3%)
- Millennium Management+427.1K
- U.S. Bancorp−33
Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PRME filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 17, 2026 | - | - | - |
| 8-K | Apr 16, 2026 | - | Analysis | - |
| 10-K | Mar 3, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 8-K | Jan 12, 2026 | - | - | |
| SC 13G | Nov 14, 2025 | - | - | |
| 10-Q | Nov 7, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 7, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 8, 2025 | Mar 31, 2025 | - | |
| 10-K | Feb 28, 2025 | Dec 31, 2024 | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
PRME SEC filings: frequently asked questions
Which institutions hold PRME stock?
As of June 30, 2026, the largest Prime Medicine, Inc. (PRME) holders among the 13F filers tracked by SignalX were Alphabet Inc ($61.1 million), BlackRock ($35.4 million), ARK Investment Management ($30.8 million), State Street Corp ($28.0 million), Vanguard Capital Management LLC ($16.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PRME's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Prime Medicine, Inc. (PRME) reported revenue of $4.6 million (up 55.3% from FY2024) and a net loss of $201.1 million. Diluted EPS was -$1.35. The figures come from the XBRL data in the 10-K.
What did PRME report in its latest 8-K?
Prime Medicine, Inc. (PRME) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026.
What are the latest PRME SEC filings?
Prime Medicine, Inc. (PRME) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on June 8, 2026.
What is PRME's SEC CIK number?
Prime Medicine, Inc. (PRME)'s SEC Central Index Key (CIK) is 1894562. EDGAR lists every PRME filing under that number.
Ask anything about PRME
The research agent reads PRME's filings, financials, insider trades and 13F holders, then answers with sources.